Mclean Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 1

Psychiatry

1100%

R&D Momentum

52/100

Pipeline Velocity

15/100

Trial Completion Rate

69/100

Pipeline Concentration

100/100

Pipeline Freshness

56/100

Activity

Recent Activity

Last 14 days

Jul 1, 2026

Completed

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia

Jul 1, 2026

Withdrawn

An Intervention to Reduce Discrepancy in Everyday Preferences

Earlier

Jun 26, 2026TrialDevelopment of Sensor-Informed Smartphone-Based Mental Health Intervention for Early Psychosis

Jun 26, 2026TrialA Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Magnesium Vitamin B6 in Combination With Treatment as Usual in First Episode of Bipolar I Disorder

Jun 26, 2026TrialEvaluating the Neurobiological Basis of Traumatic Dissociation in a Cross-Diagnostic Sample of Women With Histories of Childhood Abuse and Neglect

Jun 26, 2026TrialLeveraging Machine Learning Approaches to Understand Mechanisms of Exposure Therapy in Real-World Settings

Jun 26, 2026TrialOpen Label Extension Study of NCT06221852 of the Ketogenic Diet in Participants With First Episode Bipolar Disorder.

Mar 1, 2026TrialA Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

4 more events

Jun 1, 2025TrialInvestigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans

Feb 1, 2025TrialPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

Jun 1, 2024TrialMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

Mar 25, 2024TrialNon-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Psychiatry

Bipolar I Disorder

Magnesium vitamin B6

Psychiatry

Bipolar I Disorder

Magnesium vitamin B6Phase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)